Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + lenalidomide for newly diagnosed primary plasma cell leukemia (younger and elderly adults)
2016-003105-33Phase 2Completed
- Sponsor
- HOVON
- Start
- Jan 2018
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib and lenalidomide in plasma cell leukaemia (PCL), sponsored by HOVON. Primary endpoint: Progression-free survival. Started Jan 2018; status: completed.
02
Drugs
carfilzomiblenalidomide
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on 2016-003105-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003105-33.